1.1
Bruyand M, Vandenhende MA, Marcel G, Lazaro E, Lafon ME, Dupon M, Dabis F, Geffard S, Fleury H, Faure-Della Corte M, Bonnet F, Thiébaut R, Garrigue I.
CMV plasma DNAemia and risk of cancer among HIV-infected patients: a case-control study nested in the ANRS CO3 Aquitaine Cohort, France, 2002-2007.
J Clin Virol 2011, 50:177-180
1.2
Bruyand M, Dabis F, Vandenhende MA, Lazaro E, Neau D, Leleux O, Geffard S, Morlat P, Chêne G, Bonnet F.
HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008.
J Hepatol 2011, 55: 1058-1062
1.3
Dauchy FA, Lawson-Ayayi S, de La Faille R, Bonnet F, Rigothier C, Mehsen N, Miremont-Salamé G, Cazanave C, Greib C, Dabis F, Dupon M.
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Kidney Int 2011, 80:302-309
1.4
De Pommerol M, Hessamfar M, Lawson-Ayayi S, Neau D, Geffard S, Farbos S, Uwamaliya B, Vandenhende MA, Pellegrin JL, Blancpain S, Dabis F, Morlat P; for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort.
Int J STD AIDS 2011, 22:67-72
1.5
Richert L, Dehail P, Mercié P, Dauchy FA, Bruyand M, Greib C, Dabis F, Bonnet F, Chêne G; for the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
High frequency of poor locomotor performance in HIV-infected patients.
AIDS 2011, 25:797-805
1.6
Bruyand M, Broussy S, Vandenhende MA, Tchamgoué S, Bonnal F, Dauchy F, Greib C, Uwamaliya B, Fleury H, Dabis F et le GECSA.
Surveillance de la grippe A H1N1 chez les personnes vivant avec le VIH, Cohorte ANRS CO3 Aquitaine, 2009-2010.
BEH, 2011, n° 42
1.7
Loko MA, Bani-Sadr F, Winnock M, Lacombe K, Carrieri P, Neau D, Morlat P, Serfaty L, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group.
Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
J Viral Hepat 2011; 18:e307-314
1.8
Carrieri MP, Cohen J, Salmon-Ceron D, Winnock M.
Coffee consumption and reduced self-reported side-effects in HIV-HCV co-infected patients during PEG-IFN and Ribavirin treatment: results from ANRS CO13 HEPAVIH.
J Hepatol 2011 Aug 30. [Epub ahead of print]
1.9
Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, Spire B, Dabis F, Carrieri MP; for the ANRS-CO13-HEPAVIH Study Group.
Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: The role of the physician.
Drug Alcohol Depend 2011;116:228-232
1.10
Roux P, Fugon L, Winnock M, Salmon-Céron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri M; for the ANRS CO 13 HEPAVIH Study Group.
Positive impact of HCV treatment on ART adherence in HIV-HCV coinfected patients: one more argument for expanded access to HCV treatment for IDUs.
Addiction 2011 Aug 5. [Epub ahead of print]
1.11
Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Lascoux-Combe C, Garipuy D, Rosenthal E, Carrieri P, Dabis F, Salmon D.
Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination.
Vaccine 2011;29(47):8656-8660
1.12
Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group.
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.
J Antimicrob Chemother 2011; 66:901-911
1.13
Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M; Collaboration of Observational HIV Epidemiological Research Europe.
HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4 T-cell lymphocytes.
Blood 2011;117(23):6100-6108
1.14
CASCADE Collaboration.
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
Arch Intern Med 2011;171(17):1560-1569
1.15
Castro H, Judd A, Gibb DM, Butler K, Lodwick RK, van Sighem A, Ramos JT, Warsawski J, Thorne C, Noguera-Julian A, Obel N, Costagliola D, Tookey PA, Colin C, Kjaer J, Grarup J, Chêne G, Phillips A. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).
Risk of triple-class virological failure in children with HIV: a retrospective cohort study.
Lancet 2011;377(9777):1580-1587
1.16
Costagliola D for the PLATO II group for COHERE in EuroCoord. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.
Lancet Infectious Diseases. 2011. [E-pub ahead of print]
1.17
Cozzi-Lepri A, Paredes R, Phillips A, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner J, Lundgren J; for EuroSIDA in EuroCoord.
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI(*).
HIV Med 2011 Aug 17. [Epub ahead of print]
1.18
Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.
The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D Study.
J Infect Dis 2011;204(4):521-525
1.19
Fox ZV, Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD; EuroSIDA.
Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA.
Antivir Ther 2011;16(5):781-785
1.20
Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR; CASCADE Collaboration.
Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults.
AIDS 2011, 25(11):1395-1403
1.21
Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD; CoDe Working Group; D:A:D Study Group.
The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology.
Epidemiology 2011;22(4):516-523
1.22
Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; Eurosida Study Group.
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study.
HIV Clin Trials 2011;12(2):109-117
1.23
Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group.
Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors.
AIDS 2011;25(12):1505-1513
1.24
Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; on behalf of the CASCADE Collaboration in EuroCoord.
Time from Human Immunodeficiency Virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm3: assessment of need following changes in treatment guidelines.
Clin Infect Dis 2011;53(8):817-825
1.25
Mugavero MJ, May M, Ribaudo HJ, Gulick RM, Riddler SA, Haubrich R, Napravnik S, Abgrall S, Phillips A, Harris R, Gill MJ, de Wolf F, Hogg R, Günthard HF, Chêne G, D’arminio Monforte A, Guest JL, Smith C, Murillas J, Berenguer J, Wyen C, Domingo P, Kitahata MM, Sterne JA, Saag MS; AIDS Clinical Trial Group DACS 241 Team; AIDS Clinical Trial Group Study 5095 Team; AIDS Clinical Trial Group Study 5142 team; The Antiretroviral Cohort Collaboration.
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study.
J Acquir Immune Defic Synd 2011 ;58(3):253-260
1.26
Murray M, Hogg R, Lima V, May M, Moore D, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill M, Harris R, Reiss P, Justice A, Kirk O, Saag M, Smith C, Weber R, Rockstroh J, Khaykin P, Sterne J; for the Antiretroviral Therapy Cohort Collaboration (ART-CC).
The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
HIV Med 2011. [Epub ahead of print]
1.27
Mussini C, Cossarizza A, Sabin C, Babiker A, De Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucci M; CASCADE Collaboration.
Decline of CD4 T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals.
AIDS 2011;25(8):1041-1049
1.28
Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; The EuroSIDA Study Group.
A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy.
J Infect Dis 2011;204(5):741-752
1.29
Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercié P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M; D:A:D Study Group.
Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D Study.
HIV Med 2011;12(7):412-421
1.30
Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group.
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
HIV Med 2011;12(5):259-268
1.31
Reekie J, Gatell J, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska J, Mocroft A, for the EuroSIDA study group. Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata.
AIDS 2011;25(18):2259-2268
1.32
Soriano V, Grint D, Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L; EuroSIDA Study Group.
Hepatitis delta in HIV-infected individuals in Europe.
AIDS 2011;25(16):1987-1992
1.33
Van der Helm JJ, Prins M, del Amo J, Bucher HC, Chêne G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, Geskus RB; CASCADE Collaboration.
The Hepatitis C epidemic among HIV-positive men who have sex with men: incidence estimates from 1990 to 2007
AIDS 2011;25(8):1083-1091
1.34
Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group.
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.
AIDS 2011;25(10):1305-1315
1.35
Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kucherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, Garcia F, Judd A, Porter K, Thiébaut R, Castro H (née Green), van Sighem AI, Colin C, Kjær J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G. Impact of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project.
Lancet Infectious Diseases 2011;11(5):363-371.
1.36
Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Mller N, Mercié P, Lundgren JD, Sabin C.
Elevated triglycerides and risk of myocardial infarction in HIV-positive persons.
AIDS 2011;25(12):1497-1504
2.1
Bruyand M, Broussy S, Reigadas S, Vandenhende MA, Tchamgoué S, Bonnal F, Dauchy F, Greib C, Geffard S, Fleury H, Dabis F on behalf of the Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Surveillance of the H1N1 influenza epidemic in France: Experience of the ANRS CO3 Aquitaine Cohort, 2009-2010.
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 50]
2.2
Mehsen N, Lawson-Ayayi S, Schaeverbeke T, Pellegrin I, Mercié P, Barthe N, Geffard S, Dupon M, Pellegrin J-L, Dabis F, Groupe d’Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Cardiovascular risk and osteoporosis are associated in HIV–infected patients, ANRS C03 Aquitaine Cohort, France.
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17-20 July 2011. Roma (Italy) [Abstract TUPE 246]
2.3
Morlat P, Vivot A, Dauchy F, Asselineau J, Vandenhende MA, Lazaro E, Gérard Y, Bonnet F, Neau D, Mercié P, Déti E, Chêne G, Groupe d’Epidémiologie Clinique du Sida en Aquitaine.
Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort (2004-2008).
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17-20 July 2011. Roma (Italy) [Abstract WEPDBO104]
2.4
Pellegrin I, Bitard J, Lazaro E, Neau D, Ragnaud JM, Bonnet F, Mercié P, Dabis F, Pellegrin JL, Moreau JF, Thiébaut R, Groupe d’Epidémiologie Clinique du Sida en Aquitaine.
Contribution of cytomegalovirus (CMV)-, self-antigen-related CD8+ immune response, and s CD14 to chronic immune activation (CIA) in HIV-infected patients on prolonged successful antiretroviral therapy (CART).
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17-20 July 2011. Roma (Italy) [Abstract TUPE052]
2.5
Loko MA, Benhamou Y, Bani-Sadr F, Bicart See A, Winnock M, Dabis F, Salmon D, and ANRS CO 13 HEPAVIH Study Group.
Factors Associated with Liver Fibrosis Progression Assessed by Elastography in HIV/HCV Co-infected Patients.
18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011 Boston (USA) [Abstract Paper 927]
2.6
Roux P, Fugon L, Winnock M, Salmon-Céron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri P; for the ANRS CO 13 HEPAVIH Study Group.
Positive impact of HCV treatment initiation on adherence to HIV treatment in co-infected patients: implications for access to HCV Care.
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17-20 July 2011. Roma (Italy) [Abstract TUPE177]
2.7
Salmon D, Pambrun E, Poizot-Martin I, Winnock M, Valantin M-A, Goujard C, Loko MA, Dabis F, Sogni P, and ANRS CO 13 HEPAVIH Study Group.
HCV Treatment and CD4 Cell Count Decline, in HIV/HCV Co-infected Patients: European Cohort Collaboration.
18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011 Boston (USA) [Abstract 923]
2.8
Abgrall S, Cornish R, Mugavero M, Saag M, May M, Sterne J, and ART-CC.
Outcomes after Switch from or Interruption to First ART Regimen: The ART Cohort Collaboration.
18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011 Boston (USA) [Abstract 578]
2.9
Abgrall S, Ingle S, May M, Sterne J on behalf of the ART-CC.
Are the reasons for switching or interrupting ART in the first 6 months different from those for late switches?
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 90]
2.10
Brandt RS, Rickenbach M, Hillebregt MMJ, Fontas E, Geffard S, McManus H, Fanti I, Delforge M, Ledergerber B and Kjaer J on behalf of the D:A:D Study Group.
Improving data quality in HIV cohort collaborations – exemplified by the D:A:D Study Group.
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 59]
2.11
Cozzi-Lepri A, Paredes R, Phillips A, Kjær J, Lazzarin A, van Lunzen J, Karlsson A, Johnson M, Lundgren J, and EuroSIDA Study Group.
Predictors of virologic response to ETR-based cART regimens in a large European Cohort of HIV-infected patients.
18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011 Boston (USA) [Abstract 598]
2.12
Grint D, Peters L, Reekie J, Rockstroh J, Soriano V, Kirk O on behalf of the EuroSIDA study group.
Predictors of Hepatitis C RNA levels in HIV co-infected individuals in a prospective Cohort Study.
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 35]
2.13
Grint D, Phillips A on behalf of the EuroSIDA study. Predictors of hepatitis C viremia in co-infected individuals. 13th European AIDS Conference/EACS, 12-15 October 2011, Belgrade (Serbia). Oral presentation
2.14
Heiner C. Bucher on behalf of the OI working group of COHERE. Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected patients with sustained viral response to cART. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17-20 July 2011. Oral presentation
2.15
Ingle S, Abgrall S, May M, Sterne J for ART-CC.
Cumulative incidence of and risk factors for switching or interrupting first ART regimen and death: The antiretroviral therapy Cohort Collaboration (ART-CC).
15th International workshop on HIV observational databases 24-26 March 2011. Prague (Czech Republic) [Abstract 18]
2.16
Jarrin I and Del Amo J on behalf of the ART-CC.
Sex differences in mortality rates among treated patients: the Antiretroviral Therapy Cohort Collaboration (ART-CC).
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 15]
2.17
Kjaer J, Hillebregt MMJ, Brandt RS, Fontas E, Balestre E, Mc Manus H, Fanti I, Delforge M and Rickenbach M on behalf of the DAD study.
How to identify patients enrolled in multiple cohorts- exemplified by the D:A:D study.
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 52]
2.18
Kowalska J, Mocroft A, Reekie J, Phillips A, Reiss P, Ledergerber B, Gatell J, D’Arminio Monforte A, Lundgren J, Kirk O, for EuroSIDA Study Group.
Risk of cause-specific deaths over calendar time and according to cumulative exposure to cART.
18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011 Boston (USA) [Abstract 790]
2.19
Lodi S, D’Arminio Monforte A, Del Amo J, Abragall S, Sabin C, Porter K, Girardi E, on behalf of the CASCADE Collaboration.
Risk of tuberculosis following HIV seroconversion in low-burden tuberculosis countries.
6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 17-20 July 2011. Roma (Italy) [Abstract WEPDB0205]
2.20
May M, and Sterne J for ART-CC.
Heterogeneity among ART-CC Cohorts before and after adjustment for patient and cohort level characteristics: AIDS Events, Mortality, and Effect of CD4.
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic), [Abstract 17]
2.21
Nakagawa F, on behalf of the PLATO II Project Team of COHERE.
Calendar time trends in the incidence and prevalence of HIV-infected patients with triple-class virologic failure in Europe.
15th International workshop on HIV observational databases 24-26 March 2011. Prague (Czech Republic) [Abstract 81]
2.22
Peters L on behalf of the EuroSIDA study. Chronic hepatitis C (HCV) infection and chronic kidney disease (CKD) in HIV-infected patients in the EuroSIDA study.
13th European AIDS Conference/EACS, 12-15 October 2011, Belgrade (Serbia). Oral presentation
2.23
Reekie J on behalf of the EuroSIDA study group.
Biomarkers in patients developing Non-AIDS defining malignancies - the need for a collaboration case-control study.
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 2]
2.24
Reekie J on behalf of the EuroSIDA study.The incidence of serious non-AIDS defining infections in the EuroSIDA cohort.
13th European AIDS Conference/EACS, 12-15 October 2011, Belgrade (Serbia). Oral presentation
2.25
Ryom L, Kamara DA, Worm SW, Ross MJ, Reiss P, Fux CA, Morlat P, Moranne O, Kirk O, Smith C and Lundgren JD for the D:A:D study group. Development of a definition for Rapid Progression (RP) of renal disease in HIV-positive persons.
13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV, 14-16 July 2011, Roma (Italy). Oral presentation.
2.26
Smith C, d’Arminio Monforte A, de Wolf F, Puoti M, Dabis F, on behalf of the HCV Working Group of COHERE.
Fibrosis stage and incidence of end-stage liver disease and death in a large cohort of HIV/HCV Co-infected patients.
18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011 Boston (USA) [Abstract 965]
2.27
Soriano V on behalf of the EuroSIDA study. Hepatitis delta in HIV-infected individuals in Europe.
13th European AIDS Conference/EACS, 12-15 October 2011, Belgrade (Serbia). Oral presentation
2.28
Touloumi G, Pantazis N, Chaix M-L, Meyer L, Thiébaut R, Masquelier B, Kücherer C, d’Arminio Monforte A, Lodi S, Porter K, and CASCADE-Concerted Action on SeroConversion to AIDS and Death in Europe.
Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration.
18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011 Boston (USA) [Abstract 571]
2.29
Worm S, Tverland J, Bruyand M, Reiss P, Fontas E, El –Sadr W, Kirk O, Weber, D’Arminio Monforte A, De Wit S, Ryom L, Friis-Moller, Law M, Lundgren J, and Sabin C.
Cancers or not? Collection and preliminary assessment of non –AIDS-defining malignancies (NADMs) in the D:A:D Study.
15th International Workshop on HIV Observational Databases, 24-26 March 2011. Prague (Czech Republic) [Abstract 32]
2.30
Worm S for the D:A:D study group. Non-AIDS defining malignancies (NADM) in the D:A:D study: Time trends and predictors of survival.
13th European AIDS Conference/EACS, 12-15 October 2011, Belgrade (Serbia). Oral presentation
3.1
Bruyand M.
Etude des déterminants immunologiques et virologiques du risque de cancer chez les personnes vivant avec le VIH de la Cohorte ANRS CO3 Aquitaine.
Thèse n° 1817 pour le Doctorat de l’Université Bordeaux Segalen, 2011. Mention : Sciences, Technologie, Santé. Option : Epidémiologie et Santé Publique.
3.2
Hessamfar M.
Morbi-mortalité des femmes infectées par le VIH, à l’ère des multithérapies antirétrovirales.
Thèse pour le Doctorat de l’Université Bordeaux Segalen, 2011. Mention : Sciences, Technologie, Santé. Option : Epidémiologie et Santé Publique.
3.3
Franrenet S.
L’information dans les recherches sur la personne doit-elle encore évoluer ? Le contexte de deux cohortes de patients infectés par le virus de l’immunodéficience humaine (VIH).
Thèse pour le Doctorat de l’Université Paris Descartes, 2011. Mention Sciences de la Vie et de la Santé. Discipline : Ethique.
3.4
Sanguinet F.
La vitamine D peut-elle expliquer le lien entre perte osseuse et évènement cardiovasculaire, au cours de l’infection par le VIH?
Thèse n°3040 pour l’obtention du Diplôme d’État de Docteur en Médecine de l’Université Bordeaux Segalen.
3.5
Lejeune M.
Analyse des caractéristiques des patients perdus de vue de la Cohorte ANRS CO3 Aquitaine sur la période 2000-2010.
Rapport de Stage, 1ère année du Master Sciences, Technologies, Santé. Mention Santé Publique, ISPED, Université Bordeaux Segalen, 2011.